Clinical Trial Update: A Single and Multiple Ascending Doses Study to Evaluate the Safety, Tolerability and Pharmacokinetics of RBD7022 [Phase 1]

View source ↗

Summary

A Phase 1 ascending-dose study evaluating the safety, tolerability, and pharmacokinetics of RBD7022 in relation to hyperlipidemia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hyperlipidemia

Drugs mentioned

• RBD7022 (RBD7022)

Snippet

Sponsor: Suzhou Ribo Life Science Co. Ltd. | Conditions: Hyperlipemia | Phase 1 | Status: COMPLETED